Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Cancer Supportive Care Drugs Market: By Drug Class: G-CSFs, Erythropoietin Stimulating Agents (ESA), Antiemetics, Bisphosphonates, Opioids, NSAIDs, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Value Chain Analysis; Competitive Landscape; Industry Events and Developments
Global Cancer Supportive Care Drugs Market Outlook
The global cancer supportive care drugs market stood at a value of almost USD 22.57 billion in 2020. The market is expected to witness a steady growth during the forecast period of 2022-2027, growing at a CAGR of 1.2%.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
It is estimated that the global cancer burden has risen to 18.1 million new cases and 9.6 million deaths in 2018. The most prominent kinds of cancer with the greatest demand for supportive care drugs are lung and breast cancer.
Properties and Applications
The global cancer supportive care drugs market can be broadly categorised on the basis of its drug class into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
- G-CSFs
- Erythropoietin Stimulating Agents (ESA)
- Antiemetics
- Bisphosphonates
- Opioids
- NSAIDs
- Others
The EMR report looks into the regional markets for cancer supportive care drugs like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
It is anticipated that increased biosimilar uptake, a large number of side effects connected with cancer treatment, increased expenditure on the healthcare sector, and the accessibility to the efficient therapeutic techniques, including target-specific and tailored treatments, are driving the global cancer supportive care drugs industry further. China and India are promising locations for the development of the cancer supportive care drugs industry. Factors such as increasing biosimilar uptake, effective healthcare reforms, and low-cost bases are providing a boost to the market in these two nations.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global cancer supportive care drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- F. Hoffmann-La Roche AG
- HELSINN Healthcare SA
- Tesaro
- Novartis International AG
- Heron Therapeutics (NASDAQ: HRTX)
- Merck & Co., Inc. (NYSE: MRK)
- Amgen Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Region |
| Breakup by Drug Class | G-CSFs, Erythropoietin Stimulating Agents (ESA), Antiemetics, Bisphosphonates, Opioids, NSAIDs, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | HELSINN Healthcare SA, F. Hoffmann-La Roche AG, ROG (SWX), Tesaro, Novartis International AG, NOVN (SWX), Heron Therapeutics, HRTX (NASDAQ), Merck & Co., Inc., MRK (NYSE), Amgen Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Cancer Supportive Care Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Cancer Supportive Care Drugs Historical Market (2017-2021)
8.3 Global Cancer Supportive Care Drugs Market Forecast (2022-2027)
8.4 Global Cancer Supportive Care Drugs Market by Drug Class
8.4.1 G-CSFs
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Erythropoietin Stimulating Agents (ESA)
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Antiemetics
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Bisphosphonates
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.4.5 Opioids
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2017-2021)
8.4.5.3 Forecast Trend (2022-2027)
8.4.6 NSAIDs
8.4.6.1 Market Share
8.4.6.2 Historical Trend (2017-2021)
8.4.6.3 Forecast Trend (2022-2027)
8.4.7 Others
8.5 Global Cancer Supportive Care Drugs Market by Region
8.5.1 Market Share
8.5.1.1 North America
8.5.1.2 Europe
8.5.1.3 Asia Pacific
8.5.1.4 Latin America
8.5.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 HELSINN Healthcare SA
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 F. Hoffmann-La Roche AG (SWX: ROG)
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Merck & Co., Inc. (NYSE: MRK)
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Amgen Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Novartis International AG (SWX: NOVN)
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Cancer Supportive Care Drugs Market: Key Industry Highlights, 2016 and 2026
2. Global Cancer Supportive Care Drugs Historical Market: Breakup by Drug Class (USD Million), 2017-2021
3. Global Cancer Supportive Care Drugs Market Forecast: Breakup by Drug Class (USD Million), 2022-2027
4. Global Cancer Supportive Care Drugs Historical Market: Breakup by Region (USD Million), 2017-2021
5. Global Cancer Supportive Care Drugs Market Forecast: Breakup by Region (USD Million), 2022-2027
6. North America Cancer Supportive Care Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
7. North America Cancer Supportive Care Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
8. Europe Cancer Supportive Care Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
9. Europe Cancer Supportive Care Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
10. Asia Pacific Cancer Supportive Care Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
11. Asia Pacific Cancer Supportive Care Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Latin America Cancer Supportive Care Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
13. Latin America Cancer Supportive Care Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Middle East and Africa Cancer Supportive Care Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
15. Middle East and Africa Cancer Supportive Care Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Global Cancer Supportive Care Drugs Market Structure
Key Questions Answered in the Report
In 2020, the global cancer supportive care drugs market attained a value of nearly USD 22.57 billion.
The market is projected to grow at a CAGR of 1.2% between 2022 and 2027.
The major drivers of the industry, such as the rising demand for supportive care drugs, increased biosimilar uptake, increased expenditure on the healthcare sector, and the rising accessibility to efficient therapeutic techniques, are expected to aid the market growth.
The key market trend guiding the industry growth includes the development of the cancer supportive care drugs.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading drug classes of the product in the industry are G-CSFs, erythropoietin stimulating agents (ESA), antiemetics, bisphosphonates, opioids, and NSAIDs, among others.
The major players in the industry are HELSINN Healthcare SA, F. Hoffmann-La Roche AG, Merck & Co., Inc., Amgen Inc., and Novartis International AG, among others.
Analyst Review
The global cancer supportive care drugs market attained a value of USD 22.57 billion in 2020, driven by rising demand for supportive care drugs. Aided by the rising innovations, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 1.2%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug class, the market can be segmented into G-CSFs, erythropoietin stimulating agents (ESA), antiemetics, bisphosphonates, opioids, NSAIDs, and others. The major regional markets for cancer supportive care drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include HELSINN Healthcare SA, F. Hoffmann-La Roche AG, Merck & Co., Inc., Amgen Inc., and Novartis International AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER